
Patients with stage I triple-negative breast cancer (TNBC) who have high levels of stromal tumor-infiltrating lymphocytes (TILs) demonstrate excellent 10-year breast cancer-specific survival without chemotherapy, suggesting stromal TILs could be a useful biomarker to optimize treatment decisions in this patient population.


coremsg

Stromal tumor-infiltrating lymphocyte levels may help determine which patients with stage I TNBC can skip chemotherapy, findings from a recent registry analysis suggested.

Which Patients With Early TNBC Can Avoid Chemotherapy?

identifying-patients-with-early-stage-triple-negative-breast-cancer-who-can-safely-avoid-chemotherapy-based-on-stromal-tumor-infiltrating-lymphocyte-levels


Identifying Patients with Early-Stage Triple-Negative Breast Cancer Who Can Safely Avoid Chemotherapy Based on Stromal Tumor-Infiltrating Lymphocyte Levels
